Nimvastid (Rivastigmine)

Rivastigmine works by reversibly inhibiting the enzymes acetylcholinesterase and butyrylcholinesterase. This inhibition slows the breakdown of acetylcholine, increasing its concentration in the brain and enhancing cholinergic neurotransmission, which is essential for memory and learning.

The appropriate dose of Nimvastid is determined by the prescribing healthcare professional based on the patient’s condition, response, and tolerability. Dosage regimens are individualized and should follow the prescriber’s instructions without deviation.

There is limited clinical data on the use of rivastigmine during pregnancy or lactation. Because potential risks cannot be ruled out, the product is generally avoided in pregnant or breastfeeding women unless the benefits clearly outweigh the risks.

To order Nimvastid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nimvastid (rivastigmine) is a non‑selective cholinesterase inhibitor, similar to donepezil and galantamine but also inhibits butyrylcholinesterase. This broader activity may offer additional symptomatic benefit for some patients, though individual response varies and side‑effect profiles differ.

Nimvastid should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct light to maintain stability throughout its shelf life.

Nimvastid is taken orally, usually with food to reduce gastrointestinal irritation. The tablet (or capsule) should be swallowed whole with a full glass of water and not chewed, crushed or split unless specifically instructed by a healthcare professional.

Serious adverse events include severe bradycardia, gastrointestinal bleeding, hepatic dysfunction, acute cholinergic crisis, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for these conditions, especially during dose escalation.

Nimvastid is contraindicated in patients with known hypersensitivity to rivastigmine or any excipients, those with severe hepatic impairment, and individuals with a history of serious cardiac conduction disorders that could be worsened by bradycardia.